https://www.benevolent.com | United Kingdom | 2013 | $345.55M
BenevolentAI is a UK-based biotechnology company founded in 2013 that leverages artificial intelligence and machine learning in drug discovery. The company’s “Benevolent Platform"integrates AI throughout the drug development process and has collaborations with major pharmaceutical companies. BenevolentAI is publicly traded on the Euronext Amsterdam stock exchange and led by key individuals including CEO Joerg Moeller and co-founder Ivan Griffin.
